FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794709253> ?p ?o ?g. }

• W2794709253 endingPage "80" @default.
• W2794709253 startingPage "74" @default.
• W2794709253 abstract "This study compared the efficacy, pharmacokinetics (PK), and safety of GFF MDI (Bevespi Aerosphere®), a fixed-dose combination of glycopyrronium and formoterol fumarate dihydrate (14.4/10 μg) delivered by a metered dose inhaler (MDI) formulated using innovative co-suspension delivery technology, in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) with and without the Aerochamber Plus® Flow-Vu® valved holding chamber (VHC).In this multicenter, open-label, crossover, Phase III study (NCT02454959), patients were randomized to receive GFF MDI 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) twice daily for 7 days with and without the VHC. The primary endpoint was forced expiratory volume in 1 s area under the curve from 0 to 12 h (FEV1 AUC0-12) on Day 8. Steady state PK parameters for glycopyrronium and formoterol (AUC0-12, peak concentration [Cmax] and time to peak concentration [tmax]) were estimated from 12-h plasma concentration time data on Day 8. Safety and tolerability were also assessed throughout.Eighty patients were randomized. On Day 8, the ratio (90% confidence interval [CI]) of least squares mean (LSM) FEV1 AUC0-12 for GFF MDI with VHC (LSM = 1538 mL; n = 67) versus without VHC (LSM = 1516 mL; n = 68) was 101.4% (100.1, 102.7). PK parameters were comparable overall with a slightly higher exposure to glycopyrronium with the VHC. The AUC0-12 geometric LSM ratio (90% CI) for GFF MDI with versus without VHC was 115.99% (99.74, 134.89) for glycopyrronium and 96.66% (86.69, 107.78) for formoterol. GFF MDI with and without VHC were well tolerated with a similar adverse event profile.The magnitude of bronchodilatory effect was similar with and without a VHC following GFF MDI treatment. This, together with the PK and safety profiles, supports the use of the VHC with GFF MDI for the maintenance treatment of COPD, which could be particularly useful for patients who have difficulty with the coordination of an MDI." @default.
• W2794709253 created "2018-04-06" @default.
• W2794709253 creator A5002603430 @default.
• W2794709253 creator A5011502862 @default.
• W2794709253 creator A5027144208 @default.
• W2794709253 creator A5027975503 @default.
• W2794709253 creator A5064666568 @default.
• W2794709253 creator A5074008187 @default.
• W2794709253 creator A5077419098 @default.
• W2794709253 creator A5077936927 @default.
• W2794709253 creator A5090165536 @default.
• W2794709253 date "2018-05-01" @default.
• W2794709253 modified "2023-10-15" @default.
• W2794709253 title "Randomized study of the effects of Aerochamber Plus ® Flow-Vu ® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease" @default.
• W2794709253 cites W1492302546 @default.
• W2794709253 cites W1796604713 @default.
• W2794709253 cites W1890874870 @default.
• W2794709253 cites W1997133617 @default.
• W2794709253 cites W2040371084 @default.
• W2794709253 cites W2048426296 @default.
• W2794709253 cites W2069984535 @default.
• W2794709253 cites W2082530871 @default.
• W2794709253 cites W2086199047 @default.
• W2794709253 cites W2097967100 @default.
• W2794709253 cites W2143335419 @default.
• W2794709253 cites W2166432084 @default.
• W2794709253 cites W2167427906 @default.
• W2794709253 cites W2313458055 @default.
• W2794709253 cites W2317895461 @default.
• W2794709253 cites W2331048833 @default.
• W2794709253 cites W2336500161 @default.
• W2794709253 cites W2520775112 @default.
• W2794709253 cites W2558903543 @default.
• W2794709253 cites W2568255753 @default.
• W2794709253 cites W2591678263 @default.
• W2794709253 cites W2746644590 @default.
• W2794709253 cites W2761239349 @default.
• W2794709253 cites W2765538469 @default.
• W2794709253 doi "https://doi.org/10.1016/j.rmed.2018.03.033" @default.
• W2794709253 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29724397" @default.
• W2794709253 hasPublicationYear "2018" @default.
• W2794709253 type Work @default.
• W2794709253 sameAs 2794709253 @default.
• W2794709253 citedByCount "11" @default.
• W2794709253 countsByYear W27947092532018 @default.
• W2794709253 countsByYear W27947092532019 @default.
• W2794709253 countsByYear W27947092532020 @default.
• W2794709253 countsByYear W27947092532021 @default.
• W2794709253 crossrefType "journal-article" @default.
• W2794709253 hasAuthorship W2794709253A5002603430 @default.
• W2794709253 hasAuthorship W2794709253A5011502862 @default.
• W2794709253 hasAuthorship W2794709253A5027144208 @default.
• W2794709253 hasAuthorship W2794709253A5027975503 @default.
• W2794709253 hasAuthorship W2794709253A5064666568 @default.
• W2794709253 hasAuthorship W2794709253A5074008187 @default.
• W2794709253 hasAuthorship W2794709253A5077419098 @default.
• W2794709253 hasAuthorship W2794709253A5077936927 @default.
• W2794709253 hasAuthorship W2794709253A5090165536 @default.
• W2794709253 hasBestOaLocation W27947092531 @default.
• W2794709253 hasConcept C112705442 @default.
• W2794709253 hasConcept C126322002 @default.
• W2794709253 hasConcept C126894567 @default.
• W2794709253 hasConcept C142724271 @default.
• W2794709253 hasConcept C197934379 @default.
• W2794709253 hasConcept C204787440 @default.
• W2794709253 hasConcept C22979827 @default.
• W2794709253 hasConcept C27081682 @default.
• W2794709253 hasConcept C2776042228 @default.
• W2794709253 hasConcept C2776136866 @default.
• W2794709253 hasConcept C2776780178 @default.
• W2794709253 hasConcept C2776954882 @default.
• W2794709253 hasConcept C2778375690 @default.
• W2794709253 hasConcept C2779871671 @default.
• W2794709253 hasConcept C2780261241 @default.
• W2794709253 hasConcept C2780667556 @default.
• W2794709253 hasConcept C2781018748 @default.
• W2794709253 hasConcept C2909086917 @default.
• W2794709253 hasConcept C42219234 @default.
• W2794709253 hasConcept C44249647 @default.
• W2794709253 hasConcept C71924100 @default.
• W2794709253 hasConcept C87813604 @default.
• W2794709253 hasConceptScore W2794709253C112705442 @default.
• W2794709253 hasConceptScore W2794709253C126322002 @default.
• W2794709253 hasConceptScore W2794709253C126894567 @default.
• W2794709253 hasConceptScore W2794709253C142724271 @default.
• W2794709253 hasConceptScore W2794709253C197934379 @default.
• W2794709253 hasConceptScore W2794709253C204787440 @default.
• W2794709253 hasConceptScore W2794709253C22979827 @default.
• W2794709253 hasConceptScore W2794709253C27081682 @default.
• W2794709253 hasConceptScore W2794709253C2776042228 @default.
• W2794709253 hasConceptScore W2794709253C2776136866 @default.
• W2794709253 hasConceptScore W2794709253C2776780178 @default.
• W2794709253 hasConceptScore W2794709253C2776954882 @default.
• W2794709253 hasConceptScore W2794709253C2778375690 @default.
• W2794709253 hasConceptScore W2794709253C2779871671 @default.
• W2794709253 hasConceptScore W2794709253C2780261241 @default.
• W2794709253 hasConceptScore W2794709253C2780667556 @default.
• W2794709253 hasConceptScore W2794709253C2781018748 @default.

• next